| Applications: |
WB |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
XTP4 Positive Control is synthetically produced from the sequence and is suitable for use in western blot applications. |
| Formulation: |
Provided as 100 uL ready-to-use, in SDS-PAGE sample buffer (Laemelli's buffer) containing Tris, pH 6.8, 1 % SDS, Glycerol and Bromophenolblue blue as tracking dye. The sample is reduced by adding 2% beta mercaptoethanol. The protein concentration is |
| Dilution Range: |
WB: 1:500-1:1, 000 |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Tissue Specificity | Among normal tissues, present only in Leydig cells. Strongly up-regulated in breast cancers and in brain cancer distant metastasis (at protein level). Up-regulated in prostate cancer cells and in the higher grades of prostate adenocarcinoma (at protein level). |
| Post Translational Modifications | Isoprenylation facilitates association with the plasma membrane and enhances the migratory phenotype of cells by inducing increased filopodia formation. |
| Function | Increases cell migration by inducing filopodia formation at the leading edge of migrating cells. Plays a role in regulation of apoptosis, possibly through control of CASP3. May be involved in a redox-related process. |
| Peptide Name | Migration And Invasion Enhancer 1Hbv X-Transactivated Gene 4 ProteinHbv Xag-Transactivated Protein 4Protein C35 |
| Cellular Localisation | CytoplasmCytosolCell MembraneLipid-AnchorCytoplasmic SideConcentrates At The Leading Edge Of Migrating CellsLocalizes Outside Membrane Raft Regions |
| Alternative Peptide Names | Migration And Invasion Enhancer 1 proteinHbv X-Transactivated Gene 4 Protein proteinHbv Xag-Transactivated Protein 4 proteinProtein C35 proteinMIEN1 proteinC17orf37 proteinRDX12 proteinXTP4 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
